White House Wants To Avoid Fight On Rebates, Get Quick Passage Of Senate Rx Pricing Bill
“We’re out of time for ideas," Domestic Policy Council Director Joe Grogan says. Trump administration is pushing hard to get the Senate drug pricing bill through Congress quickly and score a major victory for the President.
You may also be interested in...
White House Domestic Policy Council Director Joe Grogan is departing at the end of May. In an interview, he talked about lessons (so far) from the COVID-19 response and the future of drug pricing policy against the backdrop of the pandemic.
Hoping to revive interest in rebate reform, PhRMA releases study saying manufacturers retain a shrinking portion of gross branded drug revenues as products move through the supply chain. The pricing distortion underscores the importance of targeting practices by payers and hospitals, the trade group argues.
Senate legislation taking aim at price increases faces uphill climb, but sponsors are hoping President Trump will mobilize more support among congressional Republicans in the coming year.